Follow Us:
Vinblastine Exporter From India

Vinblastine

Vinblastine is an anticancer medication belonging to the vinca alkaloid class of chemotherapy drugs. It is primarily used to treat Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, testicular cancer, and certain other malignancies. It works by binding to tubulin and inhibiting microtubule formation, thereby preventing cancer cells from undergoing mitosis and multiplication. This helps stop tumour growth and promotes cancer cell death. Vinblastine is administered intravenously under the supervision of an oncology specialist. Common side effects include nausea, vomiting, hair loss, constipation, and reduced blood cell counts. Serious adverse effects may include bone marrow suppression, peripheral neuropathy, and increased risk of infections. Regular monitoring of blood counts and liver function is essential during treatment.

  • Dosage Form:
  • Dosage Strength:
  • Manufacturer:
  • CAS No.:
  • Status:

Applications of Vinblastine

Vinblastine was historically used as a respiratory medicine for the symptomatic management of certain respiratory conditions. Its former uses included:

is okay

Contraindication of Vinblastine

Availability of Vinblastine

Delivery of Vinblastine

Frequently Asked Questions

The most frequently asked questions focus on import, export, documentations, and regulation for Vinblastine.

The is a pharmaceutical active pharmaceutical ingredient (API) used in manufacturing of Vinblastine.

: Provides active pharmaceutical ingredients (APIs), customized production, and OEM/ODM services with research and technical cooperation across Europe, the USA, and India via Primeera Healthcare.

  • Therapeutic Goods Administration (TGA):
  • US Food and Drug Administration (USFDA):
  • European Medicines Agency (EMA):
  • African Medicines Agency (AMA):
  • National Medical Products Administration (NMPA):
  • Central Drugs Standard Control Organization (CDSCO):

Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Vinblastine, subject to confirmation of its current regulatory status and eligibility for import into India.

Documentation Required for Vinblastine Import

The import of medicines into India is regulated by the Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The regulatory requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished formulation, or an unapproved medicine intended for an individual patient's treatment.

Import Regulations and dcoumentation for Vinblastine

  • Import Documentation Assistance:
    Support with organising commercial invoices, packing lists, manufacturer details, product specifications, certificates of analysis, and other relevant documents required for regulatory review and customs processing.

  • Regulatory Coordination:
    Assistance with identifying applicable CDSCO requirements, import authorisations, and documentation procedures, subject to the product's regulatory status and the proposed import route.
  • Shipping and Customs Coordination:
    Coordination with relevant logistics providers and customs professionals to organise shipment documentation and facilitate clearance where legally permitted.
  • Compliance Verification:
    Preliminary review of available product and shipment documentation to identify potential regulatory gaps before procurement or dispatch. Import arrangements will proceed only after the applicable permissions and restrictions have been verified.

Customs Clearance and Compliance Handling of Vinblastine Import

Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Vinblastine, subject to confirmation of its current regulatory status and eligibility for import into India.

Export Regulations and dcoumentation for Vinblastine

The export of Vinblastine from India is subject to applicable requirements under the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and relevant export, customs, and destination-country regulations. Documentation requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished pharmaceutical formulation, or a medicine intended for a specific market. Export eligibility and destination-country requirements must be verified before shipment.

Documentation Required for Vinblastine Emport

  • Export Documentation Assistance:
    Assistance with organising commercial invoices, packing lists, manufacturer details, Vinblastine specifications, certificates of analysis, and other supporting documents required for Vinblastine export and customs processing.
  • Regulatory Coordination:
    Support in identifying applicable country specific Vinblastine export requirements, relevant manufacturing and export authorisations, and destination-country registration or import approval requirements, subject to the Vinblastine regulatory status.
  • Shipping and Customs Coordination:
    Coordination with logistics providers, freight forwarders, and customs professionals to organise shipping documentation, export declarations, and customs clearance procedures where legally permitted.
  • Compliance Verification:
    Preliminary review of available Vinblastine documentation, labelling, Vinblastine manufacturing information, and destination-market requirements to identify potential regulatory gaps before dispatch. Export arrangements will proceed only after the applicable restrictions and authorisations have been verified.

Customs Clearance and Compliance Handling of Vinblastine Export

Primeera Healthcare Private Limited can provide pharmaceutical export documentation assistance, regulatory coordination, and shipping support for Vinblastine, subject to confirmation of its export eligibility under applicable Indian regulations and the import requirements of the destination country.

Product Export Support

If you have any questions or need any help, contact our Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.

Disclaimer

All Trademarks and Brands that appear on the website belong to their respective owners. Primeera Healthcare does not lay any claim on them; we only provide information.